💨 Abstract

Zydus Lifesciences reported a 30% increase in third-quarter profit, exceeding analysts' expectations, due to strong sales of generic drugs in the US market. The company's revenue from operations grew by 17%, with a 31% jump in the US, accounting for 47% of total revenue. However, growth in India slowed to 6.7% from 16% last year.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖